How should raloxifene be dosed and monitored in postmenopausal women at risk for osteoporosis or estrogen‑dependent breast cancer, and what are its contraindications?

Raloxifene Dosing and Management in Postmenopausal Women

Raloxifene should be dosed at 60 mg orally once daily for 5 years in postmenopausal women for both osteoporosis management and breast cancer risk reduction, with absolute contraindications including any history of venous thromboembolism, stroke, or TIA. 1, 2

Indications and Patient Selection

For Breast Cancer Risk Reduction

Raloxifene is appropriate for postmenopausal women ≥35 years with:

• 5-year projected breast cancer risk ≥1.66% (using modified Gail model), OR
• Lobular carcinoma in situ (LCIS) 1

The modified Gail model incorporates current age, first-degree relatives with breast cancer, number of breast biopsies, age at menarche, and nulliparity/age at first live birth 2.

For Osteoporosis

Raloxifene is recommended for postmenopausal women at high risk of fracture who:

• Have low risk of deep vein thrombosis, AND
• Are candidates in whom bisphosphonates or denosumab are not appropriate, OR
• Have high risk of breast cancer (dual benefit scenario) 3

Critical limitation: Raloxifene reduces vertebral fractures by 30-50% but has no proven efficacy for nonvertebral fractures 4, 5. Therefore, avoid raloxifene in women at high risk of hip or other nonvertebral fractures—use bisphosphonates or denosumab instead.

Dosing Regimen

Standard dose: 60 mg orally once daily 1, 2

• Can be taken any time of day, with or without food 2
• Duration: 5 years for breast cancer risk reduction 1
• May be continued beyond 5 years in women with osteoporosis where breast cancer risk reduction becomes a secondary benefit 1

Supplementation requirements: Add calcium (1500 mg/day elemental calcium) and vitamin D if dietary intake is inadequate 2

Absolute Contraindications

Raloxifene must never be used in women with: 1, 2

• Active or past history of venous thromboembolism (DVT or PE)
• History of stroke or transient ischemic attack
• Prolonged immobilization (surgical recovery, bedrest)
• Pregnancy, potential pregnancy, or breastfeeding (though this is postmenopausal context)
• Premenopausal status 1

The FDA black box warning emphasizes a 3-fold increased risk of venous thromboembolism and increased risk of fatal stroke, particularly in women with documented coronary heart disease 2, 6.

Monitoring Requirements

Before Initiating Treatment

• Breast examination and mammogram 2
• Assess venous thromboembolism risk factors
• Evaluate stroke risk (particularly in women with coronary disease)

During Treatment

• Continue regular breast exams and mammograms per standard screening guidelines 2
• Immediate workup of any abnormal vaginal bleeding (though raloxifene does not stimulate endometrium, unlike tamoxifen) 1
• Monitor for signs/symptoms of venous thromboembolism
• For osteoporosis: Consider bone density reassessment, though specific intervals not mandated by guidelines

Fracture Risk Reassessment

After 5 years of treatment in osteoporotic women, reassess fracture risk:

• If high risk persists: Continue raloxifene 3
• If low-to-moderate risk: Consider discontinuation 3

Common Pitfalls and Caveats

Hot flushes: Occur in ~25% of patients (vs 18% placebo), typically mild and within first few months 7. This makes raloxifene inappropriate for women with bothersome vasomotor symptoms—consider alternative agents 3.

Leg cramps: Common adverse effect, generally mild 4, 8

No effect on noninvasive breast cancer: Raloxifene only reduces invasive ER-positive breast cancer risk by 76% overall (90% for ER-positive tumors specifically) 8. It does not reduce ER-negative breast cancer risk 2.

BRCA mutation carriers: No data available on efficacy in women with BRCA1/BRCA2 mutations 2

Not for treatment: Raloxifene is not indicated for treating invasive breast cancer or reducing recurrence risk 2

Risk-Benefit Discussion

Optimal candidates for raloxifene are postmenopausal women who:

• Need vertebral fracture protection (not hip fracture protection)
• Have elevated breast cancer risk
• Have no history of thromboembolism or stroke
• Do not have bothersome hot flushes
• Cannot tolerate or prefer to avoid bisphosphonates

Avoid raloxifene in favor of other agents when:

• Nonvertebral fracture risk is the primary concern (use bisphosphonates/denosumab)
• History of venous thromboembolism exists (absolute contraindication)
• Patient has documented coronary disease or high stroke risk
• Patient is premenopausal

The decision requires individualized assessment weighing the 30-50% vertebral fracture reduction and 76% invasive breast cancer reduction against the 3-fold increased venous thromboembolism risk 1, 2, 4.